Abstract
Background India has the highest absolute number of stillbirths worldwide. Despite the high burden and preventable nature, stillbirth is not high on the health agenda including the absence of stillbirths in the Global Burden of Disease (GBD) study estimates. We assessed the disease and economic burden of stillbirth in India.
Methods In this retrospective analysis, the number of stillbirths, live births, and life expectancy was derived from the Health Management Information System (HMIS) 2019 for India and its 21 states. Additionally, values from the civil and sample registration systems were used for secondary analysis. Two stillbirth rates were calculated-still live birth rate (SLBR) using live births and still total birth rate (STBR) using total births i.e., live and stillbirths. We calculated stillbirth-adjusted life expectancy (SALE). For disease burden, measured by disability-adjusted life-years (DALYs), we multiplied live births with the absolute difference of SALE and live-birth life expectancy. We calculated the stillbirth contribution of under-5 DALYs derived from GBD 2019. Economic burden was calculated under the value of life-year (VLY) approach by multiplying stillbirth DALYs with per capita domestic product. Three values were calculated based on different domestic product values from the Reserve Bank of India and National Health Accounts data for 2019.
Results As per HMIS, India had 263342 stillbirths. Nationally, the SLBR and STBR were 12.4 and 12.25, respectively. Stillbirths decreased the overall life expectancy at birth by 0.85 years. Stillbirths contributed to 18.1 million DALYs and the economic burden was INR 7.7 trillion in 2019. Stillbirths contributed 22% to under-5 DALYs. Eight states (30.9%) contribute to more than 50% of disease and economic burden.
Conclusion These findings suggest a high disease and economic burden of stillbirth in India with across-state variations. Incorporating burden metrics in child health policies could improve resource allocation.
Study Question This study estimates the disease and economic burden of stillbirth in India in 2019
What’s already known India has the highest absolute number of stillbirths. Despite the high burden and preventable nature, the stillbirth burden is not included in global or national estimates. No previous studies have looked at the disease burden of stillbirth. While previous studies have looked at the economic burden of stillbirth in the High-Income Countries, they present no value for India.
What this study adds This study looks at the stillbirth disease burden in terms of disability-adjusted life-years (DALYs) and the percentage contribution of stillbirth to under-5 DALYs. The economic burden of stillbirth was calculated by the value of life-years (VLYs) approach. The disease burden of stillbirth was 18 million DALYs, with stillbirth contributing 22% to the total under-5 DALYs. The economic burden was NR 7.7 trillion (USD 109.38 billion) for India in 2019.
Competing Interest Statement
Siddhesh Zadey (SZ) serves on the State Mental Health Policy Drafting Committee for Maharashtra, India, the Board of ASAR, and the Advisory Board of Nivarana. SZ is currently the Chair of G4 Alliance SOTA Care in South Asia Working Group and has received honoraria from Think Global Health, Harvard Public Health Magazine, and The Hindu for writing. Sweta Dubey serves on the Board of ASAR. Vidhi Wadhwani has no competing interests to disclose.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data availability statement: The data used and produced in the manuscript can be found on Harvard Dataverse at - https://doi.org/10.7910/DVN/UVMO51.
Funding statement: No funding
Conflict of interest disclosure: Siddhesh Zadey (SZ) serves on the State Mental Health Policy Drafting Committee for Maharashtra, India, the Board of ASAR, and the Advisory Board of Nivarana. SZ is currently the Chair of G4 Alliance SOTA Care in South Asia Working Group and has received honoraria from Think Global Health, Harvard Public Health Magazine, and The Hindu for writing. Sweta Dubey serves on the Board of ASAR. Vidhi Wadhwani has no competing interests to disclose.
Ethics approval statement: Not applicable
Patient consent statement: Not applicable
Permission to reproduce material from other sources: Not applicable
Data Availability
All data produced are available online at https://doi.org/10.7910/DVN/UVMO51
